However, Yi Hu et al. did not evaluate the treatment options for NSCLC patients with brain or liver metastases after resistance to EGFR-TKIs and did not examine the efficacy comparison with chemotherapy + anti-angiogenic therapy which was commonly used in clinical practice. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.